Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ingrid Oyarzun"'
Autor:
Clara Quiroga, Georthan Mancilla, Ingrid Oyarzun, Anita Tapia, Mia Caballero, Luigi A. Gabrielli, Denisse Valladares-Ide, Andrea del Campo, Pablo F. Castro, Hugo E. Verdejo
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2020)
Hypertension (HTN) is a public health concern and a major preventable cause of cardiovascular disease (CVD). When uncontrolled, HTN may lead to adverse cardiac remodeling, left ventricular hypertrophy, and ultimately, heart failure. Regular aerobic e
Externí odkaz:
https://doaj.org/article/de0cef626ea04e7c8789987a2aa86831
Autor:
Hugo Verdejo, Georthan Mancilla, Ingrid Oyarzun, Jheimmy Diaz, Mario Bustamante, Clara Quiroga, Luan Américo-Da-Silva
Publikováno v:
The FASEB Journal. 32:4681-4695
Bone integrity depends on a finely tuned balance between bone synthesis by osteoblasts and resorption by osteoclasts. The secretion capacity of mature osteoblasts requires strict control of proteostasis. Endoplasmic reticulum-associated degradation (
Low Gene Dosage ofCdc42Is Not Associated with Protein Dysfunction in Patients with Colorectal Cancer
Autor:
Adam Aguirre, Ximena Calderón, Claudia Hoepfner, Jaime Meléndez, Andrés Azócar, Karin Alvarez, Matías González-Quiroz, Ingrid Oyarzun, Francisco López-Köstner, Rodrigo Quera
Publikováno v:
DNA and Cell Biology. 35:819-827
High incidence of Rho Cdc42-GTPase overexpression has been found in Colorectal Cancer (CRC) samples, suggesting its potential role in tumor development. However, no conclusive studies have shown the lack of mutations and/or copy number of Cdc42 gene
Autor:
Georthan Mancilla, Ingrid Oyarzun, Rocio Artigas, Clara Quiroga, Ignacio Wichmann, Hugo Verdejo, Pablo Castro
Publikováno v:
Circulation Research. 121
Advances in bioinformatics has provided us with large databases that characterize the complex genetic and epigenetic changes associated with human diseases. The use of data mining strategies on public access databases to identify previously unknown d
Autor:
Mario Bustamante, Ingrid Oyarzun, Georthan Mancilla, Clara Quiroga, Hugo E Verdejo, Pablo Castro
Publikováno v:
Circulation Research. 121
Galectin-3 (gal-3) is a β-galactoside-binding protein used as a prognostic biomarker in chronic heart failure (CHF) patients. Genetic and pharmacologic studies show that gal-3 is required for cardiac remodeling in animal models of CHF, suggesting an